Gut Microbiota Mediated Molecular Events and Therapy in Liver Diseases

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2021 Jan 28

PMID 33505139

Citations 14

Authors

Xiaoqiang Qi

Ming Yang

Joseph Stenberg

Rahul Dey

Leslie Fogwe

Muhammad Shawkat Alam

Eric T Kimchi

Kevin F Staveley-OCarroll

Guangfu Li

Affiliations

Soon will be listed here.

Abstract

Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases.

Citing Articles

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease.

Pasta A, Formisano E, Calabrese F, Marabotto E, Furnari M, Bodini G Microorganisms. 2025; 13(2).

PMID: 40005608 PMC: 11857840. DOI: 10.3390/microorganisms13020241.

Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota.

Sokal-Dembowska A, Jarmakiewicz-Czaja S, Filip R Int J Mol Sci. 2024; 25(20).

PMID: 39456969 PMC: 11508831. DOI: 10.3390/ijms252011187.

The gut microbiota-bile acid axis in cholestatic liver disease.

Sun D, Xie C, Zhao Y, Liao J, Li S, Zhang Y Mol Med. 2024; 30(1):104.

PMID: 39030473 PMC: 11265038. DOI: 10.1186/s10020-024-00830-x.

Guardians of the Gut: Harnessing the Power of Probiotic Microbiota and Their Exopolysaccharides to Mitigate Heavy Metal Toxicity in Human for Better Health.

Dahiya P, Kumari S, Behl M, Kashyap A, Kumari D, Thakur K Probiotics Antimicrob Proteins. 2024; 16(6):1937-1953.

PMID: 38733461 DOI: 10.1007/s12602-024-10281-9.

and NAFLD: pathophysiology and therapy.

Zhang J, Zhou J, He Z, Li H Front Microbiol. 2024; 15:1288856.

PMID: 38572244 PMC: 10988783. DOI: 10.3389/fmicb.2024.1288856.

References

Azad M, Sarker M, Li T, Yin J . Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018; 2018:9478630. PMC: 5964481. DOI: 10.1155/2018/9478630. View

Zapater P, Cano R, Llanos L, Ruiz-Alcaraz A, Pascual S, Barquero C . Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology. 2009; 137(5):1669-79.e1. DOI: 10.1053/j.gastro.2009.07.058. View

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

Oikonomou T, Papatheodoridis G, Samarkos M, Goulis I, Cholongitas E . Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol. 2018; 24(34):3813-3820. PMC: 6141334. DOI: 10.3748/wjg.v24.i34.3813. View

Song I, Yang Y, Inokuchi-Shimizu S, Roh Y, Yang L, Seki E . The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2017; 142(1):81-91. PMC: 5790193. DOI: 10.1002/ijc.31029. View

Hou W, Syn W . Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis. Front Cell Dev Biol. 2018; 6:150. PMC: 6240744. DOI: 10.3389/fcell.2018.00150. View

Bajaj J, Heuman D, Sanyal A, Hylemon P, Sterling R, Stravitz R . Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013; 8(4):e60042. PMC: 3615021. DOI: 10.1371/journal.pone.0060042. View

Xie G, Wang X, Wang L, Wang L, Atkinson R, Kanel G . Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology. 2011; 142(4):918-927.e6. PMC: 3618963. DOI: 10.1053/j.gastro.2011.12.017. View

Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N . Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget. 2018; 9(11):9925-9939. PMC: 5839411. DOI: 10.18632/oncotarget.24066. View

10.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

11.

Schnabl B, Brenner D . Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24. PMC: 3996054. DOI: 10.1053/j.gastro.2014.01.020. View

12.

Yang J, Han D, Xie C, Zhao Y, Ma X . Endotoxins enhance hepatocarcinogenesis induced by oral intake of thioacetamide in rats. World J Gastroenterol. 2002; 4(2):128-132. PMC: 4688633. DOI: 10.3748/wjg.v4.i2.128. View

13.

Mullen K, Sanyal A, Bass N, Poordad F, Sheikh M, Frederick R . Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2013; 12(8):1390-7.e2. DOI: 10.1016/j.cgh.2013.12.021. View

14.

Yuan M, Xu Y, Chen L, Li X, Qin J, Shen Y . TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer. 2015; 15:245. PMC: 4435918. DOI: 10.1186/s12885-015-1262-5. View

15.

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

16.

Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli M . Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015; 8:309-25. PMC: 4675645. DOI: 10.2147/CEG.S89999. View

17.

Chen L, Xu Y, Zhou J, Wu Y, E Q, Zhu Y . TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells. Oncol Rep. 2012; 28(1):200-6. DOI: 10.3892/or.2012.1791. View

18.

Hayashi H, Sakai T . Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol. 2011; 300(5):G729-38. PMC: 3094136. DOI: 10.1152/ajpgi.00013.2011. View

19.

Zhang C, Yuan W, He P, Lei J, Wang C . Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2017; 22(48):10512-10522. PMC: 5192262. DOI: 10.3748/wjg.v22.i48.10512. View

20.

Chi G, Feng X, Ru Y, Xiong T, Gao Y, Wang H . TLR2/4 ligand-amplified liver inflammation promotes initiation of autoimmune hepatitis due to sustained IL-6/IL-12/IL-4/IL-25 expression. Mol Immunol. 2018; 99:171-181. DOI: 10.1016/j.molimm.2018.05.005. View